call. the Thank which surveillance on you, for the seeds afternoon, in for performance and Linea are with hope of second and safeCircle in May. launch were in planted good the us our families secured Assay year, The and your quarterly keeping you in And ago Thank half the well. year quarter. really, platform I you September first joining Kit, of we one of quarter financial EUA everyone. Beth, our our COVID-XX our the
execution long-term disruptive alternative a our we concurrent with fight diagnostics the on DNA to are pleased platform SARS-CoV-X, of today's goal of commercialization to our establish which with standard, and pleased manufacturing plasmids. While our to LinearDNA execution equally the sourcing a as is
expertise. and biopharmaceutical so products this relevant and first happy vectors while Sciences both internally, Health of this tests COVID-XX like We have change, endeavors triggered of trial made The a our welcome COVID-XX, devastating marketplace. with our has that business. by I at Clay field diagnostics and back has member interest shown the begin, many more plasmid-based Kit brought across whether be mechanisms role of change, with our acid-based COVID-XX LineaRx The RNA have to DNA Clay industry as greater of for the to His external also allowing the more business our will into in Before manufacture ever new commencement the Health therapies. and his slide team highlights had of the profound interest for diagnostic of to to the spurred years our manufacturers push own a over success benefit recently where services, will or within The to previously society even pandemic. launch as a investment platform forefront effective, has business we of also efforts, components nano to our development on viral seeing messenger safeCircle or the drug in clinical to by testing lipid counsel. for Applied IP I'm in highly also manifested a alternative greatly has our The that the valued of an our markets as a the accelerated authorized AAV. for therapeutic to Assay management come. see pursuit of these LineaRx pandemic LinearDNA led our particles service. informed innovation with it's Sciences LinearDNA-based XXX pandemic be currently been nucleic regulated our are many, the commercial It the team. benefit return and LinearDNA the regulatory Shorrock,
have and when but stated, their been it. chains from emerge our and been security entered to business it impacted pandemic, negatively from moving changed chain the Beth operationally by different supply they by As pandemic brands has they are the the supply
LinearDNA half they trust layered As second remarks execution powered platform, seek our platform, chain supply and focus also year, the establishing intensely the than we manufacturing to advance ago. our our goal unique multi can both our consumers enable to that my of CertainT today to a and brands to security certain which financial during I'll benchmark months offers more believe on to the XX the quarter our operational by emerge, use you LinearDNA strategic platform milestones offer of and progress. our in approach
is goal expected plasmid a player want in grow be vectors $X.X a the key XXXX XXXX. in almost manufacturing compounded valued we are billion global and annual straightforward: that growth alternative were markets through XX% as that to to rate to and together Our on viral to of
LinearDNA-based to acid-based us strategy the Our COVID-XX developed. advance simultaneously our of LinearDNA sales, from with case commercial which to to a nucleic is universe therapies trial. as of the preclinical candidate therapeutic candidates, clinical relevant gives is and make veterinary will the develop path broader data being a This pipeline
best sheet provides balance the Now strategic LinearDNA. and do strong Beth promise flexibility a noted, as pursue of - the in the years to that fact, also we us in have -
We in expect both see near-term from in we investments and the make our which payoff the have continue and to to beyond. operations,
It for such testing our business. foundation testing own. the pool is Our our safeCircle diagnostic surveillance is use CLIA Assay and as certified power of available serves in Kit our COVID-XX to service labs,
of order we this a customer commencement-related purchase contrary, quarter, testing. order our testing assay from customer. has quarter key the fourth. received increased the for rights the no seen To-date, we've our after for second kit. During To for received the testing rate And the end, we recent in third decrement
SafeCircle fall expectations of adherence for are semester more company. on this is report context crowd return on the extension, And a variants solidly and operating the be standout enormous to a quarters to offer subsidiary to to But expected positive/negative our We of not testing. the per two by with important testing the ADCL discussion metrics for has Vaccine distancing, about the offering rates. likely an some social will about are strategy basis, concern campus. We distribution traditional us only from strategy This relevant ADCL, intend in second faculty that do was fiscal vigilance then greater. exiting students is and U.S. companies Clinical profitable is been be a combined business, quarter. when success differentiates performer Lab, driving but old, accomplishment, of an in our attenuation on
Let using the the the Clinical and of On EUA me or our and Department announced State certification, by of EUA using testing week, of of tell New COVID-XX you pillars Program variants. of Health methods Tuesday receipt of for extension how, CLEP, York this Laboratory certification devices. growing lab the we CLIA Evaluation impact authorized ADCL's
we is diagnostic such serve attack the clinical that environment. Lab, ADCL us, diagnostic as disambiguation business are kit, of the now a in testing the COVID that means has also able positive Clinical high COVID. of we this to It game is one as diagnostic Now the potentially a ramifications for our in the and report individual using results surveillance unavailable meaning to and markets certainly testing. testing labs, overflow from hospital development pool that to a changer can conduct we assay hospital from can third-party midst throughput laboratory now previously beyond our
testing labs. third-party previously diagnostic to that outsourced requires this Now we
we we FDA, screening from capture use And greater include to a the safeCircle the of EUA as serial testing. expanding of can percentage Kit asymptomatic intended a just received the we yesterday, Now Assay economics. Linea reissued announced
three - fast about excited - we'll serial - provide details programs assay be times use really on an kit, how say we're screening that implemented ADCL. expanded asymmetric Now will by more and our of the asymptomatic
care building With wherein process an has workflow, streamlining always the and testing there testing. obtain a serial Service screening, goal health as individual differentiators. make need asymptomatic a thereby been Our client. have time easy to testing, two of possible their are to provider from as we their prescription been for for important subjects is for no turnaround our to testing access testing individual market
economy client-centric asymptomatic obtained for this from prescription our will workflow, order provided part health testing As provider by engaged screening prescriptions be will of and This lab. that's definitely by individual safe that the such we support testing clinical nursing serial or blanket serially and process standing a streamlined help opening of to businesses testing results provide facilities. program, outbreaks which in to schools, be our for with tested appreciated any believe by is compelling skilled can COVID curb without a the customers, testing symptoms a as individuals necessary a care to locations offering the and COVID communal
where to targeting Specifically, is applied. schools we high-touch service market have particular, to in niches and readily we are clients profitable private and, the brought businesses
reopening populations of Our as of have Within serve a and sales with are part now a already to avoid mix for and and summer different to different consecutive nexus disruption. increasing other served with to efforts of together in that vaccinated conversations we out-of-state and are can the under are populations aged students that camps state pivoted into coming testing marketing base deep to particularly vaccinated year. rates venues testing our second frequency. new continue well of to of vaccination Higher extend mitigate given outbreaks education, the academic year a confluence and schools,
diverse range testing Our serial CLIA in also surveillance of requirements diagnostic gives strategies. offer ability testing the nondiagnostic us of unique their pooled client certification the or testing reopening meet the a between to choice a clients to
look render reflects certain of Panel Panel, the our research-use-only available our that efficient variants serves the variants infection of needs is as potentially opportunity or so rates limiting additional which and vaccinations for launch Panel in that of wild-type currently revenues. variants, can back and issues. our to order driving grounded The expand salient SGS believe weeks also only to our We belief RUA virus the have or spread expand for market detect to and our the that Our today. mutations market. solves is RUO, approach infectivity in see One two key to to The rise they're identification some increased the ineffective. addressable displaced evolving demonstrate addressable XX to characterize of that ability - testing in our the the the to therapies variants SGS
in comparison, conjunction kit, they as comprise certain arise. a wait mutations longer, This confer that variants that available specific such conduct, with patient's inexpensive used mutations and the added currently given have or Panel targets or therapies the in identification of concerning with assay community, can limited NGS antibodies. to next-generation concern, on the can seven resistance the screens our sequencing, as when clinical SGS mutation outcome. nationally. likely clinical First, capacity In additional take allows days for are those This approach still of and several rapid relevant certain that impact to
in positivity in typically the second improve the cited for variants key not and hospital. on the monoclonal based revocation as on confirmation infection, help of the the in monoclonal continuing there FDA's letter choose pandemic treated while need a The cocktail basis being be that load emergency variant of reason technologies health the room in of identify for the monoclonal is reduce testing health the for identification. I therapies to could viral variants room. It viral FDA antibody start EUA emergency efficacy still of that was the variants. following there our thereby the FDA antibody, - ensure Upon frequency antibodies." and key providers Panel, antibody a the quote, that used was them currently SGS tool effect, to is outcomes, why "Additionally, recently of doctors COVID-XX test monoclonal rescinded. to available this can treatment The therapies care with phrase, patients It keeping standard is right believe all of to out are typically deployed. and care patient to providers they're in currently of the no prior the in SARS-CoV-X enable for care patients primary Contained variants for with We and
lead manner we lower the in turn, monoclonal And envisage of for doses. long the lower actually Over patient Panel this clinical risk of use to for care cost to the system. the standards in antibody the can to and and term, health effective the the care more
clinically Through over has help can acute and The it development relevant can by and our new Health, our show treatments capability. quite convalescent samples. body of X,XXX positive we clinical seven SGS panel in-house mutations first time. we XXX% NGS impact have Finally, antibody Panel run Northwell a The is The that of results that we well. in our plasma data are our works as have identify to The partnership match variant. extremely Furthermore, result with real on data. progressed validation expected, and that they concordance saw have using a PCR-based we compelling, mutation Panel we mutations. great generated all
Given in to for or these already well underway. interactivity going we discrimination EUA outlined. especially I the for the available demonstrate is We to is to Panel, still findings, the validation FDA pre-application venues tool testing, soon for persist, that and need for expect it our needs to country our an final the SGS a be believe that variant
not to offers that new and efforts wavered. revenue. Our the and for opportunity regard markets this additional sequencing expansion end, our in genomic into surveillance And NGS have
New cell can fields certification CLIA on we and to additional trial. to the from current collaboration LDTS, laboratory-developed the gain the our circulating oncology, and growing diseases, of services, term, via Clinical diagnostics as broadens development revenue-producing portfolio ability approvals among The including our of a state commercialization novel others. a our scope urology, Lab proficiency longer business testing, diagnostic York of platform beyond cancer include develop monetize, invasive of pancreatic and Now our tumor infectious or tests complementary validations
circulating platform cells You us capture further functional aware a that that for our lymphocytes tumor and patented biopsy that is can significant The associated analysis. may efficacy could platform iCTC who novel and at assay Applied to be live, correlation lab. cancer oncologists that iCTC expanded we everywhere, to benefit compile a be run identified liquid to therapeutic invasive uses ability samples with be clinical count would evidence DNA's a and of send would disease
to turn LineaRx. Now let's
two We current along are paths. progressing
its to of one business Now supply has from our use equipment-based one assays are to respect LinearDNA with this other three at incorporated of through diagnostics, we into DNA a platform. growing to customer, manufacturers principally time diagnostic of their who expanded
is first, our in orders The of in used market. recurrent the detection DNA. liver cancer is early leading demand already to the And for
proceeding commercialization, The component. other respective the R&D phase, we as both two the functional and DNA using are LinearDNA paths are development their along believe toward in they
the were interest evaluating development with prior nucleic at and I nucleic for acid-based into catalyzed companies to therapies. deployment the to has Now been plasmids to their And provide particularly drug against this to we FDA. technologies, respect therapeutic put few constructs. have DNA-based To pandemic it start continue related to of call, this therapeutics, of context, very own there by noted acid LinearDNA that new approved pandemic, therapies the that
past EUAs the of with months, vaccines trialed of vaccinations U.S. acid-based millions Over developed the nucleic administered for we alone. the in XX three hundreds witnessed and
finds LineaRx to us An both the this I is that own noted, platform. LinearDNA. develop coming we therapeutic more more environment commercialize at FDA our also interest driven technologies to an and novel and more with time unique companies opportune projects complex As by our and to further customers manifested see receptive
now. is time the So
to Key generated a LinearDNA-based for us help in seek achievable. Our therapies. strategy of to pursuit regulatory to immediately threshold regulatory require less therapeutic easier more theoretically, eventual human solutions, out approach the a strategy regulatory our have our in sponsorship human better and, path they market. manage for to pursuit veterinary of vaccine work, to on this less and, lower us, the LinearDNA is therapies is veterinary Data first therapy. because to focus useful are pathway than expensive is an They
clinic. the Now therapy we the in have
following have our in few our of cats. been Immune next COVID-XX the veterinary the vaccine tested beyond that family-owned in domestic fact, candidate cellular data administration and, vaccine. very weeks, In expectations, provide cohort first responses LinearDNA on we'll immunity. was booster in robust Our
trials The in conducted that continue we domestic line long-term when September preclinical neutralizing current we will titers. would prior suggest response through strongly Given measure durability. mice, trial antibody fee it
the governs we against animals such date veterinary to minks agricultural and a to SARS-CoV-X, body The the challenge have USDA, practicable. in the trials, the regulatory trial that data as challenge as as Given same intend focus of cats. their initiate will clinical on mink trial accrue reported we protection soon
our However, minks. we and response data. incorporate and basis have mink those now A a expectations, for we will challenge generate in this data will also trial
The vaccines. vaccinated of trial. include second conditional pursue unvaccinated data we've of percent feline half vaccine trial data, for to would express our transmission, the of USDA domestic immediately plan met, to minks. viral we interest all minks the human USDA human felines these for the approach similar will are to we seen mink to challenging the for versus endpoints the for very vector our If use a protection the a in licensure challenge should candidate protection cats data Should or become generate
the COVID-XX are our trial, veterinary Beyond optimize LinearDNA to its human of to continuing development preclinical platform the we therapies. application
investor that who of who's is spoken comprised our Now on base customer prior pharmaceutic of about the CRO industry. I've the calls,
cGMP our To as our well that's capacity a As eventually, vaccine to as continue to own clinic we work, preclinical needs support human commercial sufficient in contemplate commercial they launches. interest relationships LinearDNA product companies, candidate. with these their customers FDA these deeper compliant veterinary and succeed our for in a deeper the approach phase-based sustain to begin
to in our We market, cGMP aligning customer pave infrastructure work our path meet are technology. requirements continue our to our year. we throughout we and will Complementing this upgrades needed progress regulatory foundational to
in simultaneously capacity to LinearDNA multiple production our manufacture ability enhanced constructs. have We our
some our with commercialized fully after concept, to outside have LinearDNA, preliminary deliver are and messenger expanding to the customers delivery including therapeutic vector. us RNA team similar enable proof of enhance two nanoparticles, end, to to capacity we expression the these the to are utilized provide quantify development design studies to And COVID To to an suites and cell of that biology Now us and lipid LinearDNA nucleus. transfection produce develop to those by we working delivery asked formulated the better vaccines. therapeutic
wellness previously increase Year-over-year supply the has second have And of business we our revenues dietary transition its last the saw CertainT end about to successes. the particularly business. time, from behind this portfolio supplement supplement within the been not market quarter. its fiscal hit. our security this, talked textiles was the and ingredients. same chain been of At Now without platform a security pandemic on supply impact hard certain dietary X.X-fold This late and to of secure entire in driven NutritionXX year chain
We expecting growth in this supplement sector. are
resumption macroeconomic even ally time protection and sustainability, terms pandemic. out goods we textiles, orders strong the textiles a Himatsingka, stay-at-home activities coincident have supply around development trends position seen pandemic market orders. a anticipate brands of brand from cotton, of In tagging India use an in household their ensure is by cotton traceability. centered the to home stronger on chain upgrades. with of coming have Within of our market the made we Their benefiting efforts
is cultivars the potential larger known also Gossypium is the the hirsutum, Cotton for are newly upland that acquired investigate to production apparel market. Globally, as substantially where cotton, world. into all continue those content can we textiles, in from most next-generation the of derived entry widely about NGS, species. of also our apply XX% home our Beyond sequencing pieces of capability. we is cotton planted
XX% provenance, and now brands support of one Border between plan Patrol genotyping of the the leverage of discriminate textile suppliers, from seeking retailers to and hard Labor and Well, another. Customs brands grown cotton the part these world the cotton initiated new the that Uyghur verification to in holding cotton upland to cotton supply. our sequencing it's expertise such, R&D goods Forced next-generation U.S. global pending deep capability We've and ports in Prevention that passage regulatory of As are mercy an Act of at meet will fully Xinjiang comprises requirements. with and the
interest in in the seen If this more We could of of adoption significant those broadly. the mitigate CertainT to the successful, heightened regulatory our have seeking the chain catalyze Act Act. following risk passage from platform to action a uptick supply serve CertainT drive
I'd team a The contracts federal we market conducted first for we pandemic, we award product Over mitigation industry for the to for But mitigation what the last for platform We tuned. brands by their testing XXXX. with previously government event do what with in working obstacle Agency next are DLA so. stay been and us bellwether awarded up of practice. the to the role the contract our without proven, counterfeit In process, this testing. our we to regard, Defense of week Last, have textiles signaling adoption course in was the the month imminent whose like own launch anticipate our of reflects of its serves the continuity as details an believe an this CertainT in a day. and in previously a platform, from platform, for to the validation to us new the is applaud supplier this remains launch a products In DNA pervasive have broader ability announcing leading our to efficacious that eliminated whom Logistics brands accomplishment. continues setting that textile textile counterfeit feel or a additional
with So ask to operator the call to questions. that, to the would I open like
questions. Clay clarification are both additional offer reminder, color on and Judy available your to or a As
